Nutex Health Inc. (NUTX) Stock Price & Analysis
Nutex Health Inc. (NUTX) rose 0.74% to USD 135.4 as of June 10, 2026 at 03:07 UTC, according to Nexqual real-time market data.
NUTX last closed at USD 134.41; the session ranged USD 131.15–137.99 on volume of 108,631 shares. Market capitalization is $931.73M, with a 52-week range of USD 77.21–193.07 (NCM). Source: Nexqual, June 10, 2026 at 03:07 UTC.
Key Statistics (as of June 10, 2026 at 03:07 UTC)
| Price | USD 135.4 |
|---|---|
| Change | ▲ 0.74% (up) |
| Previous Close | USD 134.41 |
| Open | USD 134.41 |
| Day Range | USD 131.15 – 137.99 |
| 52-Week Range | USD 77.21 – 193.07 |
| Volume | 108,631 shares |
| Market Cap | $931.73M |
| Exchange | NCM |
Technical Analysis (NUTX)
Nexqual's technical model rates NUTX "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:07 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.65 (neutral) |
| vs SMA50 | Above (USD 118.59) |
| MACD | 3.73 (positive) |
Analyst Ratings (NUTX)
Wall Street analysts rate NUTX "Strong Buy" based on 4 analysts, with a mean price target of USD 235.5 (range USD 175–300), per Nexqual as of June 10, 2026 at 03:07 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 235.5 |
| High Target | USD 300 |
| Low Target | USD 175 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (NUTX)
| Next Earnings Date | 2026-07-30 |
|---|---|
| Revenue Estimate | $214.99M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 5.74 vs est 5.56 ▲ beat |
| 2025-12-31 | USD 1.62 vs est 5.56 ▼ miss |
| 2025-09-30 | USD 7.76 vs est 1.95 ▲ beat |
| 2025-06-30 | USD 5.23 vs est -5.43 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financials & Fundamentals (NUTX)
| Total Revenue | $879.95M |
|---|---|
| Revenue Growth (YoY) | +2.20% |
| Gross Margin | +50.58% |
| Operating Margin | +37.54% |
| Profit Margin | +10.95% |
| ROE | +53.65% |
| Debt / Equity | 78.97 |
| Current Ratio | 3.14 |
| Total Cash | $207.35M |
| Total Debt | $349.09M |
| Free Cash Flow | $168.75M |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financial Health Score (NUTX)
Nexqual rates Nutex Health Inc.'s overall financial health "Strong" across five dimensions, as of June 10, 2026 at 03:07 UTC.
| Growth | Strong — Revenue +82% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 51%, operating 38% |
| Balance Sheet | Mixed — $207M cash vs $349M debt |
| Cash Flow | Strong — FCF $169M, 19% margin |
| Efficiency | Strong — ROE 54%, ROA 28.6% |
Ownership (NUTX)
| Insider Ownership | +29.06% |
|---|---|
| Institutional Ownership | +42.60% |
| Shares Outstanding | 6.88M |
| Float | 4.30M |
| Short % of Float | +24.47% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Leadership (NUTX)
Nutex Health Inc. is led by Thomas T. Vo (age 52), Chairman of the Board & CEO, per Nexqual as of June 10, 2026 at 03:07 UTC.
| Chairman of the Board & CEO | Thomas T. Vo (age 52) |
|---|---|
| President & Director | Warren Hosseinion (age 53) |
| Chief Financial Officer | Jon C. Bates (age 54) |
| Chief Operating Officer | Wesley Bamburg FACHE |
| Director of Compliance | LaTanya Brackens |
Major Backers & Investors (NUTX)
Notable institutional backers of Nutex Health Inc. include American Century Companies Inc, Pertento Partners LLP, Topline Capital Management, LLC, according to Nexqual as of June 10, 2026 at 03:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| American Century Companies Inc | 5.5% |
| Pertento Partners LLP | 5.43% |
| Topline Capital Management, LLC | 2.58% |
| Millennium Management | 1.3% |
| UBS Group AG | 1.01% |
| Winmill & Co. Inc | 0.95% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.9% |
| Vanguard Group | 6.29% |
| State Street | 1.79% |
| Geode Capital | 1.77% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
From Nutex Health Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Based on the information and data we provide to HaloMD, using a proprietary data driven process, HaloMD submits the required documentation to the CIDRE through the federal portal. • Eligibility Determination.
- HaloMD, using proprietary data analysis and benchmarking, determines the appropriate offer amount on our behalf. • Independent Review .
- We believe our business, partnership and operations model enables us to compete favorably.
- Human Capital Management Attracting, developing, and retaining talented people who embrace our culture, execute our strategy, and enable us to compete effectively in our industry is critical to our success.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ILAG | Intelligent Living Application | USD 3.73 | ▲ 6.57% |
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 4.95 | ▲ 10.24% |
| REVB | Revelation Biosciences, Inc. | USD 1.04 | ▲ 5.05% |
| VRAX | Virax Biolabs Group Limited | USD 0.19 | ▼ 11.64% |
| KPRX | Kiora Pharmaceuticals, Inc. | USD 2.59 | ▲ 3.6% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:07 UTC. This page is informational and not investment advice.